• event

    Workshop to Develop a Research Agenda for Assessing Vector Control to Prevent Dengue

February 2-3, 2015 - Annecy (France)

This meeting was designed to follow up on a first workshop concerning the status of new dengue control strategies, held in November 2013. Participants reviewed currently available dengue control tools and strategies, providing expert opinion on the most effective ones targeting the primary urban dengue vector, Aedes aegypti, which can be utilized in combination with vaccination.

Continuing to focus on the vector control approach with the largest impact

The workshop’s overriding goal was to reach consensus on what vector control tools and strategies have the biggest impact on the reduction of DENV transmission. Another objective of the meeting was to address the design of trials, either alone or in combination with vaccination.

A triple focus to advance scientific understanding

The workshop was organized around three pillars:

  • A questionnaire was used to obtain expert opinion on the relative effectiveness of vector control interventions
  • Reviews of major dengue and malaria control interventions, dengue epidemiology, dengue vaccines, and trial design were presented
  • A recommendation on currently available vector control strategies that should be coupled with dengue vaccination was presented

Workshop outcomes

Of currently available methods, indoor residual spraying (termed “targeted IRS” or TIRS, to distinguish it from malaria IRS interventions) was thought to be most effective, although insecticide resistance would reduce efficacy in certain situations and must be prospectively evaluated. Experts concluded that TIRS is the best available strategy to control urban populations of Ae. aegypti and prevent dengue. While there is evidence TIRS significantly reduces populations of adult Ae. aegypti, randomized controlled trials (RCTs) with epidemiological-endpoint data have not been conducted. Moreover, TIRS associated with larvae control could provide the highest effectiveness.

It was agreed that the “gold standard” trial design is an RCT. The working group also made several other recommendations.

Progress towards reducing transmission of the virus

PDC’s expectation is that when an effective DENV vaccine is commercially available, the public health community will continue to rely on vector control because the two strategies complement and enhance one another. The work accomplished by workshop participants supports efforts to determine which vector control approaches, when utilized in combination with vaccination, will have the greatest impact on reduction of DENV transmission.

Download full summary

Speakers & Participants

  • Nicole Achee, Uniformed Services University of the Health Sciences / University of Notre Dame
  • Kate Antrobus, Lion’s Head
  • Roberto Barrera, CDC
  • Thomas Burkot, James Cook University
  • David Chadee, University of the West Indies
  • Greg Devine, Queensland Institute of Medical Research
  • Benjamin D’Hont, PDC
  • Catherine Dutel, PDC
  • Timothy Endy, Upstate Medical University
  • Duane Gubler, PDC / Duke University
  • Joachim Hombach, WHO
  • Immo Kleinschmidt, London School of Hygiene & Tropical Medicine
  • Andrew Lane, LANE medical writing services
  • Audrey Lenhart, CDC
  • Steve Lindsay, Durham University
  • Mathias Mondy, IVCC
  • Amy Morrison, University of California
  • Alan Perkins, University of California
  • Robert Reiner, Indiana University
  • Paul Reiter, Pasteur Institute
  • Scott Ritchie, James Cook University
  • Peter Ryan, Monash University
  • Mitra Saadatian-Elahi, PDC
  • Thomas W. Scott, University of California
  • François Simondon, IRD
  • Daniel Strickman, Bill & Melinda Gates Foundation
  • Rémy Teyssou, PDC
  • Kirsten Vannice, WHO
  • Gonzalo Vazquez-Prokopec, Emory University
  • Raman Velayudhan, WHO
  • Simon Warner, OXITEC Ltd

Program – Day 1

09h00 – 12h00

General opening session and introduction (T. Scott)

Conclusions from 2013 ASTMH meeting (Washington) (N. Achee)

Prioritized list of vector control for dengue control:

  • Feasibility matrices (S. Ritchie, G. Devine, D. Chadee)

New insecticide formulations/methods in development (A. Lenhart)

Lessons learned from vector control assessments for malaria (T. Burkot)

13h00 – 17h00

Measuring epidemiological impact for assessing efficacy (S. Lindsay)

Lessons learned from dengue prevention programs:

  • Traditional dengue control (A. Morrison)
  • Wolbachia (P. Ryan)
  • Spatial repellants (N. Achee)
  • Lethal ovitraps (R. Barrera)
  • RIDL (S. Warner)

How to define and implement appropriate metrics (D. Smith)

Program – Day 2

09h00 – 10h30

Develop a study design (T. Scott)

The vaccine perspective (T. Endy)

The vector control perspective (S. Ritchie)

11h00 – 12h00

Study design options and considerations (Part 1) (R. Reiner)

13h00 – 16h30

Study design options and considerations (Part 2) (R. Reiner)

16h30 – 17h00